ABUS News and Press, Arbutus Biopharma Corporation From 12/13/22

Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharma...

Arbutus Biopharma ( NASDAQ: ABUS ) stock was trading in the green on Wednesday following its Q3 results . Total revenue grew +78.1% Y/Y to $5.95M, but missed analysts estimates. The company said the increase was mainly due to $2.3M of revenue recognition fro...

Arbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Conference Call January 1, 2022 8:45 a.m. ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - President and Chief Executive Officer David Hastings - Chief Financial Off...

Arbutus Biopharma press release ( NASDAQ: ABUS ): Q3 GAAP EPS of -$0.12 beats by $0.01 . Revenue of $5.95M (+78.1% Y/Y) misses by $3.23M . As of September 30, 2022, the Company had cash, cash equivalents and investments in marketable securities of $190.2 millio...

Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple addi...

WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Ar...

The following slide deck was published by Arbutus Biopharma Corporation in conjunction with this event. For further details see: Arbutus Biopharma (ABUS) presents at AASLD 2022 - Slideshow

Arbutus Biopharma ( NASDAQ: ABUS ) rose 8.1% after a judge denied a Moderna ( NASDAQ: MRNA ) motion to dismiss a lawsuit from from Arbutus seeking damages related to patent's for the Covid-19 vaccine. Judge Mitchell Goldberg's denial was in a court filing viewe...

HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced HBV immune response Data to...

Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022 WARMINSTER, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging it...